PTC Therapeutics (NASDAQ: PTCT) saw its stock soar 5.58% in pre-market trading on Wednesday, following the release of its impressive third-quarter 2025 financial results and the successful launch of its new drug, Sephience.

The biopharmaceutical company, focused on rare diseases, reported a surprising profit for the quarter ended September 30, 2025. PTC Therapeutics posted earnings of $0.20 per share, a significant turnaround from a loss of $1.39 per share in the same period last year. This result far exceeded analyst expectations, which had projected a loss of $1.37 per share. Total revenue for the quarter reached $211.0 million, representing a 7.23% increase year-over-year and surpassing the analyst consensus estimate of $185.25 million.

A key driver of the company's strong performance was the successful launch of Sephience, its new therapy for phenylketonuria (PKU). The drug generated global revenue of $19.6 million in its first quarter on the market, with $14.4 million coming from the US and $5.2 million from ex-US markets. As of September 30, 2025, 341 patients were on commercial therapy worldwide, with 521 Patient Start Forms submitted by 141 unique US prescribers. The company also highlighted Sephience's superior efficacy in lowering blood phenylalanine levels compared to existing treatments. In light of these results, PTC Therapeutics narrowed its full-year 2025 revenue guidance to $750-$800 million, signaling confidence in its continued growth trajectory.

The market's positive reaction was further bolstered by favorable analyst updates. Following the earnings release, several firms raised their price targets for PTC Therapeutics. Notably, RBC increased its target price to $82 from $70, TD Cowen raised it to $63 from $50, and Jefferies lifted its target to $86 from $77. These upgrades reflect growing confidence in the company's financial performance and the potential of its product pipeline.